Syndax Pharmaceuticals Inc (SNDX) - Total Assets
Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) holds total assets worth $551.79 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SNDX total equity for net asset value and shareholders' equity analysis.
Syndax Pharmaceuticals Inc - Total Assets Trend (2011–2024)
This chart illustrates how Syndax Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Syndax Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Syndax Pharmaceuticals Inc's total assets of $551.79 Million consist of 83.2% current assets and 16.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.3% |
| Accounts Receivable | $13.87 Million | 1.9% |
| Inventory | $366.00K | 0.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Syndax Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Syndax Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Syndax Pharmaceuticals Inc's current assets represent 83.2% of total assets in 2024, a decrease from 91.8% in 2011.
- Cash Position: Cash and equivalents constituted 21.3% of total assets in 2024, down from 77.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
Syndax Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Syndax Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Syndax Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.64 | 6.99 | 15.84 |
| Quick Ratio | 4.40 | 7.07 | 15.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $415.64 Million | $355.43 Million | $279.99 Million |
Syndax Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Syndax Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.43 |
| Latest Market Cap to Assets Ratio | 2.29 |
| Asset Growth Rate (YoY) | 18.3% |
| Total Assets | $724.82 Million |
| Market Capitalization | $1.66 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Syndax Pharmaceuticals Inc's assets at a significant premium (2.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Syndax Pharmaceuticals Inc's assets grew by 18.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Syndax Pharmaceuticals Inc (2011–2024)
The table below shows the annual total assets of Syndax Pharmaceuticals Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $724.82 Million | +18.26% |
| 2023-12-31 | $612.88 Million | +23.26% |
| 2022-12-31 | $497.24 Million | +10.58% |
| 2021-12-31 | $449.66 Million | +49.58% |
| 2020-12-31 | $300.61 Million | +373.22% |
| 2019-12-31 | $63.52 Million | -24.32% |
| 2018-12-31 | $83.94 Million | -38.81% |
| 2017-12-31 | $137.19 Million | +25.84% |
| 2016-12-31 | $109.01 Million | +21.26% |
| 2015-12-31 | $89.90 Million | +601.49% |
| 2014-12-31 | $12.82 Million | -24.88% |
| 2013-12-31 | $17.06 Million | +1029.87% |
| 2012-12-31 | $1.51 Million | -68.45% |
| 2011-12-31 | $4.79 Million | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. … Read more